MedPath

The Efficacy of Transversus Abdominis Plane Block Versus Wound Infiltration for Analgesia After Cesarean Delivery:

Not Applicable
Conditions
Cesarean Section Complications
Registration Number
NCT04874168
Lead Sponsor
Ain Shams University
Brief Summary

This study aimed to compare bilateral ultrasound-guided TAP block with single-shot local anesthetic wound infiltration for analgesia after cesarean delivery performed under spinal anesthesia

Detailed Description

This double-blind, randomized controlled trial aimed to compare bilateral ultrasound-guided TAP block to single-shot local anesthetic wound infiltration for analgesia after cesarean delivery performed under spinal anesthesia. This will be done by measuring VAS (visual analogue score) for pain after ceserian section at2, 4, 6, 12, 24 hours .

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
210
Inclusion Criteria
  • Women undergoing cesarean section under spinal anesthesia
  • Aged ≥19 years and > 40 years .
  • Gestational age ≥ 37 Weeks .
  • Informed Consent From the Patient .
Exclusion Criteria
  • Body mass index (BMI) ≥40 kg/m2 ..
  • History of recent opioid exposure .
  • Hypersensitivity to any of the drugs used in the study .
  • Significant cardiovascular, renal, or hepatic disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The degree of pain at rest ;From 2 hours to 24 hours postoperatively

using an Visual analogue scale (VAS) scores for pain intensity reported on 0-10 point scale for analysis. (0 = no pain and 10 = the worst possible pain) .

Secondary Outcome Measures
NameTimeMethod
The time to the first postoperative opioid doseat 2, 4, 6, and 12 hours.

cumulative opioid consumption

Trial Locations

Locations (1)

Ain Shams University

🇪🇬

Cairo, Alabbasia, Egypt

Ain Shams University
🇪🇬Cairo, Alabbasia, Egypt
ahmed G elnajar, md
Contact
0201092672757
a7medgamal2020.ag@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.